chemotherapy

 Adding Carboplatin To Chemotherapy May Improve Survival

 Adding Carboplatin To Chemotherapy May Improve Survival

According to research reported at the American Urological Association, 2020 Virtual Experience,” adding carboplatin to docetaxel chemotherapy for men with metastatic castration-resistant prostate cancer (mCRPC) and who failed either Xtandi or Zytiga may improve their survival.

AR-V7 Liquid Biopsy Coming of Age

Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.  

When this happens, the question that comes is what should be the next treatment?  Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).  

Treatments for Advanced Prostate Cancer May Work Better in Black Men

Black men are more likely to be diagnosed with prostate cancer at a younger age, with an advanced stage, and with a higher grade. Black men are also twice as likely to die from prostate cancer than white men. Despite these facts, these two studies show that certain treatments for advanced metastatic prostate cancer may work better in black men. 

Confirming The Value of Early Docetaxel in Men With Metastatic Hormone-Sensitive Prostate Cancer

Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT.